시장보고서
상품코드
1961067

심혈관 기기 시장 : 기기 유형별, 용도별, 최종사용자별, 지역별 - 시장 규모, 산업 역학, 기회 분석, 예측(2026-2035년)

Global Cardiovascular Devices Market: By Device Type, Application, End User, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035

발행일: | 리서치사: Astute Analytica | 페이지 정보: 영문 260 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 심혈관 기기 시장은 견조한 성장세를 보이고 있으며, 2025년에는 시장 규모가 745억 8,000만 달러에 달할 것으로 예상됩니다. 이 놀라운 시장 규모는 향후 10년간 거의 두 배로 증가하여 2035년까지 1,573억 2,000만 달러에 달할 것으로 예상됩니다. 이러한 성장은 2026년부터 2035년까지 예측 기간 동안 CAGR 7.70%에 해당하며, 기술, 규제, 운영 등 여러 요인으로 인한 강력하고 지속적인 성장을 반영하고 있습니다.

이러한 빠른 시장 성장을 이끄는 주요 요인 중 하나는 펄스 필드 절제술(PFA) 및 첨단 구조적 심장 치료와 같은 혁신적인 기술의 도입입니다. 이러한 혁신적인 치료 옵션은 기존 수술에 비해 덜 침습적이고, 더 효과적이고 안전한 대안을 제공함으로써 심혈관질환 관리 방식을 변화시키고 있습니다. 이러한 기술의 성공과 임상 현장에서의 채택 확대는 전 세계 심혈관 기기의 수요 증가에 기여하고 있습니다.

주목할 만한 시장 동향

심혈관 기기 시장은 고도로 통합되어 있으며, 소수의 주요 기업이 시장을 독점하고 있습니다. Medtronic,Abbott,Boston Scientific,Edwards Lifesciences 등의 대기업은 큰 시장 점유율과 영향력을 가지고 있으며, 업계 내 혁신과 성장의 방향을 결정하고 있습니다. 이들 기업은 특히 구조적 심장 솔루션, 전기생리학의 발전, AI를 활용한 진단 도구에 중점을 두고 차세대 기술 개발에 많은 투자를 하고 있습니다.

메드트로닉은 시장을 선도하는 기업으로서 탄탄한 재무 실적과 성장세를 자랑하고 있습니다. 2026년 2분기, 메드트로닉은 34억 4,000만 달러의 심혈관 관련 매출을 기록하여 9.3%의 견조한 유기적 성장을 달성했습니다. 이러한 괄목할 만한 성장은 Sphere-9 펄스필드 절제술(PFA) 시스템과 Evolut FX 경피적 대동맥 판막 시스템의 성공적인 확장에 기인합니다.

구조적 심장 기기 분야의 순수 리더로 인정받고 있는 에드워드 라이프사이언스(Edwards Lifesciences)도 2025년 2분기 매출 15억 3,000만 달러로 11.9% 증가하며 견조한 실적을 기록했습니다. 이러한 성장은 에드워드의 핵심 부문인 밸브 치료에 대한 지속적인 수요를 뒷받침하고 있습니다. 이 회사의 지속적인 성공은 심혈관 기기 시장에서 구조적 심장 중재술의 중요성을 강조하고, 이 분야를 전문으로 하는 기업에게 지속적인 기회가 존재한다는 것을 시사하고 있습니다.

핵심 성장 요인

심혈관질환의 유병률 증가는 장기적으로 심혈관 기기에 대한 지속적인 수요 증가를 보장합니다. 미국에서만 2030년까지 약 1,210만 명이 심방세동 진단을 받을 것으로 예상되며, 이는 이 흔한 심장 박동 장애의 영향을 받는 인구가 크게 증가하고 있음을 반영합니다. 또한, 2024년 기준 미국 성인의 약 1억 2,790만 명이 심혈관질환을 앓고 있는 것으로 추정되며, 이는 심혈관질환이 공중 보건에 미치는 광범위한 영향력을 보여줍니다.

새로운 기회 트렌드

인공지능(AI) 기반 진단 기술의 혁신은 질병을 감지하고 관리하는 정확성과 효율성을 높여 심혈관 기기 시장을 크게 확장하고 있습니다. AccuRhythm AI와 같은 기술은 임상의가 복잡한 심혈관 데이터를 분석하는 방식을 혁신하여 부정맥 및 기타 심장 질환을 보다 빠르고 정확하게 진단할 수 있도록 돕습니다. 머신러닝 알고리즘과 고급 데이터 처리를 활용하여 의료 전문가가 정보에 입각한 의사결정을 내리고, 환자 결과를 개선하며, 임상 워크플로우를 효율화할 수 있도록 지원하는 AI 기반 툴입니다.

최적화 장벽

FDA 및 국제 규제기관의 엄격하고 시간이 오래 걸리는 승인 절차는 심혈관 기기 시장에 큰 도전이 되고 있습니다. 새로운 임상시험과 제품 출시의 안전성과 유효성을 보장하기 위해 필수적인 이러한 절차는 혁신적인 제품이 시장에 출시되기까지 장기간 지연되는 경우가 많습니다. 이러한 규제는 환자의 건강 보호에 매우 중요하지만, 장기간에 걸친 규제는 업계 내 혁신의 속도를 늦출 수 있습니다. 이러한 규제 환경은 대기업만큼 풍부한 자원과 자본을 보유하고 있지 않은 중소기업에 특히 큰 영향을 미치는 경향이 있습니다.

목차

제1장 주요 요약 : 세계의 심혈관 기기 시장

제2장 보고서 개요

제3장 세계의 심혈관 기기 시장 개요

제4장 경쟁 상황 대시보드

제5장 세계의 심혈관 기기 시장 분석

제6장 북미의 심혈관 기기 시장 분석

제7장 유럽의 심혈관 기기 시장 분석

제8장 아시아태평양의 심혈관 기기 시장 분석

제9장 중동 및 아프리카의 심혈관 기기 시장 분석

제10장 남미의 심혈관 기기 시장 분석

제11장 기업 개요

제12장 부록

KSM 26.03.30

The global cardiovascular devices market is witnessing robust growth, with its valuation reaching USD 74.58 billion in 2025. This impressive market size is expected to nearly double over the next decade, with projections estimating it will reach USD 157.32 billion by 2035. This growth corresponds to a compound annual growth rate (CAGR) of 7.70% during the forecast period from 2026 to 2035, reflecting strong and sustained expansion driven by multiple factors across technological, regulatory, and operational domains.

One of the primary forces fueling this rapid market growth is the introduction of revolutionary technologies such as pulsed field ablation (PFA) and advanced structural heart therapies. These innovative treatment options are transforming how cardiovascular diseases are managed, offering less invasive, more effective, and safer alternatives to traditional procedures. The success and increasing clinical adoption of these technologies are contributing to heightened demand for cardiovascular devices globally.

Noteworthy Market Developments

The cardiovascular devices market is highly consolidated, with a handful of key players dominating the landscape. Leading companies such as Medtronic, Abbott, Boston Scientific, and Edwards Lifesciences hold significant market share and influence, shaping the direction of innovation and growth within the industry. These firms are heavily investing in the development of next-generation technologies, focusing particularly on structural heart solutions, electrophysiology advancements, and AI-powered diagnostic tools.

Medtronic stands out as the market leader, demonstrating strong financial performance and growth. In the second quarter of fiscal year 2026, Medtronic reported cardiovascular revenue of $3.44 billion, reflecting a robust 9.3% organic growth. This impressive expansion is largely attributed to the successful scaling of its Sphere-9 Pulsed Field Ablation (PFA) system and the Evolut FX transcatheter aortic valve system.

Edwards Lifesciences, recognized as a pure-play leader in structural heart devices, also showcased strong performance with $1.53 billion in sales for the second quarter of 2025, marking an 11.9% increase. This growth underscores the sustained demand for valve therapies, a core segment for Edwards. Their continued success highlights the critical importance of structural heart interventions in the cardiovascular devices market and signals ongoing opportunities for companies specializing in this area.

Core Growth Drivers

The rising prevalence of cardiovascular diseases guarantees a sustained and growing demand for cardiovascular devices in the long term. In the United States alone, it is projected that approximately 12.1 million people will be diagnosed with Atrial Fibrillation by 2030, reflecting a significant increase in the population affected by this common heart rhythm disorder. Furthermore, as of 2024, nearly 127.9 million US adults were living with some form of cardiovascular disease, underscoring the widespread impact these conditions have on public health.

Emerging Opportunity Trends

Innovation in artificial intelligence (AI)-based diagnostics is significantly expanding the cardiovascular devices market by enhancing the accuracy and efficiency of disease detection and management. Technologies such as AccuRhythm AI are revolutionizing the way clinicians analyze complex cardiovascular data, enabling faster and more precise diagnosis of arrhythmias and other heart conditions. By leveraging machine learning algorithms and advanced data processing, these AI-driven tools support healthcare professionals in making informed decisions, improving patient outcomes, and streamlining clinical workflows.

Barriers to Optimization

The rigorous and time-consuming approval processes imposed by the FDA and international regulatory bodies present significant challenges to the cardiovascular devices market. These procedures, which are essential to ensure the safety and efficacy of new clinical trials and product launches, often result in extended delays before innovative products can reach the market. While these regulations are critical for protecting patient health, the lengthy timelines involved can slow down the pace of innovation within the industry. This regulatory environment tends to disproportionately impact smaller firms, which may lack the extensive resources and capital reserves that larger companies possess.

Detailed Market Segmentation

By Device Type, the therapeutics and surgical devices category secured a commanding position within the cardiovascular devices market, capturing an impressive 77.5% share of total revenue. This strong dominance can be attributed to a significant transformation in medical practice, where there is a clear and growing preference for minimally invasive interventions over traditional open surgery. This shift reflects advancements in technology, improved patient outcomes, and a focus on reducing recovery times and associated risks.

By Application, the coronary artery disease sector held a dominant position within the global cardiovascular devices market, reflecting the ongoing critical importance of this medical condition. Coronary artery disease, a form of ischemic heart disease, continues to be the leading cause of death and disability worldwide. This persistent prevalence drives sustained demand for specialized cardiovascular devices designed to diagnose, treat, and manage the condition effectively.

By End User, hospitals stand out as the main purchasers of cardiovascular devices in today's market, serving as the central hub for acquiring and utilizing these critical medical products. Their role is particularly crucial because they manage the vast majority of emergency cardiovascular cases, including severe conditions like ST-Elevation Myocardial Infarctions (STEMI). Such emergencies demand swift and effective medical intervention, which in turn drives a substantial and urgent need for cardiovascular devices.

Segment Breakdown

By Device Type

  • Diagnostic & Monitoring
  • ECG
  • Holter Monitors
  • Event Monitors
  • Implantable Loop Recorders
  • Echocardiogram
  • Pet Scan
  • MRI
  • Cardiac CT
  • Doppler Fetal Monitors
  • Therapeutic & Surgical Devices
  • Pacemakers
  • Stents
  • Catheters and accessories
  • Guidewires
  • Cannulae
  • Electrosurgical Procedures
  • Valves
  • Occlusion Devices
  • Others

By Application

  • Cardiac Arrhythmia
  • Coronary Artery Disease
  • Heart Failure
  • Others

By End User

  • Hospitals
  • Specialty Clinics
  • Others

By Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • South America

Geography Breakdown

  • North America maintains a strong and commanding presence in the global cardiovascular devices market, holding a substantial 45.68% share as of 2025. This prominent position is anchored by two main factors: significant localized demand and a highly developed healthcare infrastructure. In the United States alone, an estimated 127.9 million adults were managing cardiovascular conditions in 2024, creating an enormous and ongoing demand for cardiovascular devices. This large patient population ensures a steady and expanding market, as continuous treatment and intervention are necessary for effective disease management.
  • Additionally, the North American market, particularly the US, has seen a rapid and aggressive shift toward advanced, high-value cardiovascular therapies such as Pulsed Field Ablation (PFA). This innovative treatment approach has become a key driver of revenue growth in the region. For instance, Boston Scientific, a leading medical device company, generated over USD 1 billion in early revenue primarily due to the swift adoption of PFA technology within the US market. This rapid uptake highlights both the readiness of healthcare providers to embrace cutting-edge solutions and the region's capacity to support the commercialization of novel therapies, further solidifying North America's leadership in the cardiovascular devices sector.

Leading Market Participants

  • Abbott
  • BIOTRONIK SE & Co. KG
  • Boston Scientific Corporation
  • Canon Medical Systems
  • B. Braun SE
  • Cardinal Health
  • Medtronic
  • LivaNova PLC
  • Siemens Healthcare GmbH
  • Edwards Lifesciences Corporation
  • GE Healthcare
  • W. L. Gore & Associates, Inc.
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Cardiovascular Devices Market

Chapter 2. Report Description

  • 2.1. Research Framework
    • 2.1.1. Research Objective
    • 2.1.2. Market Definitions
    • 2.1.3. Market Segmentation
  • 2.2. Research Methodology
    • 2.2.1. Market Size Estimation
    • 2.2.2. Qualitative Research
      • 2.2.2.1. Primary & Secondary Sources
    • 2.2.3. Quantitative Research
      • 2.2.3.1. Primary & Secondary Sources
    • 2.2.4. Breakdown of Primary Research Respondents, By Region
    • 2.2.5. Data Triangulation
    • 2.2.6. Assumption for Study

Chapter 3. Global Cardiovascular Devices Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Raw Material Suppliers (Medical-Grade Metals, Polymers, Electronic Components)
    • 3.1.2. Component Manufacturers (Sensors, Catheters, Leads, Valves)
    • 3.1.3. Device Manufacturers (Stents, Pacemakers, Defibrillators, Heart Valves)
    • 3.1.4. Distributors & Healthcare Providers (Hospitals, Cardiac Centers, Clinics)
    • 3.1.5. End Users (Patients with Cardiovascular Diseases, Ambulatory Care Settings)
  • 3.2. Industry Outlook
    • 3.2.1. Rising Prevalence of Cardiovascular Diseases & Aging Population
    • 3.2.2. Increasing Adoption of Minimally Invasive Procedures
    • 3.2.3. Technology Trends (AI-Enabled Monitoring, Wearable Devices, Biocompatible Materials)
    • 3.2.4. Expansion of Healthcare Infrastructure in Emerging Markets
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
  • 3.6. Market Attractiveness Analysis
    • 3.6.1. By Product Type
  • 3.7. Actionable Insights (Analyst's Recommendations)

Chapter 4. Competition Dashboard

  • 4.1. Market Concentration Rate
  • 4.2. Company Market Share Analysis (Value %), 2025
  • 4.3. Competitor Mapping & Benchmarking

Chapter 5. Global Cardiovascular Devices Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Device Type
      • 5.2.1.1. Key Insights
        • 5.2.1.1.1. Diagnostic & Monitoring
          • 5.2.1.1.1.1. ECG
          • 5.2.1.1.1.2. Holter Monitors
          • 5.2.1.1.1.3. Event Monitors
          • 5.2.1.1.1.4. Implantable Loop Recorders
          • 5.2.1.1.1.5. Echocardiogram
          • 5.2.1.1.1.6. Pet Scan
          • 5.2.1.1.1.7. MRI
          • 5.2.1.1.1.8. Cardiac CT
          • 5.2.1.1.1.9. Doppler Fetal Monitors
        • 5.2.1.1.2. Therapeutic & Surgical Devices
            • 5.2.1.1.2.1.1. Pacemakers
            • 5.2.1.1.2.1.2. Stents
            • 5.2.1.1.2.1.3. Catheters and accessories
            • 5.2.1.1.2.1.4. Guidewires
            • 5.2.1.1.2.1.5. Cannulae
            • 5.2.1.1.2.1.6. Electrosurgical Procedures
            • 5.2.1.1.2.1.7. Valves
            • 5.2.1.1.2.1.8. Occlusion Devices
            • 5.2.1.1.2.1.9. Others
    • 5.2.2. By Application
      • 5.2.2.1. Key Insights
        • 5.2.2.1.1. Cardiac Arrhythmia
        • 5.2.2.1.2. Coronary Artery Disease
        • 5.2.2.1.3. Heart Failure
        • 5.2.2.1.4. Others
    • 5.2.3. By End User
      • 5.2.3.1. Key Insights
        • 5.2.3.1.1. Hospitals
        • 5.2.3.1.2. Specialty Clinics
        • 5.2.3.1.3. Others
    • 5.2.4. By Region
      • 5.2.4.1. Key Insights
        • 5.2.4.1.1. North America
          • 5.2.4.1.1.1. The U.S.
          • 5.2.4.1.1.2. Canada
          • 5.2.4.1.1.3. Mexico
        • 5.2.4.1.2. Europe
          • 5.2.4.1.2.1. Western Europe
            • 5.2.4.1.2.1.1. The UK
            • 5.2.4.1.2.1.2. Germany
            • 5.2.4.1.2.1.3. France
            • 5.2.4.1.2.1.4. Italy
            • 5.2.4.1.2.1.5. Spain
            • 5.2.4.1.2.1.6. Rest of Western Europe
          • 5.2.4.1.2.2. Eastern Europe
            • 5.2.4.1.2.2.1. Poland
            • 5.2.4.1.2.2.2. Russia
            • 5.2.4.1.2.2.3. Rest of Eastern Europe
        • 5.2.4.1.3. Asia Pacific
          • 5.2.4.1.3.1. China
          • 5.2.4.1.3.2. India
          • 5.2.4.1.3.3. Japan
          • 5.2.4.1.3.4. South Korea
          • 5.2.4.1.3.5. Australia & New Zealand
          • 5.2.4.1.3.6. ASEAN
          • 5.2.4.1.3.7. Rest of Asia Pacific
        • 5.2.4.1.4. Middle East & Africa
          • 5.2.4.1.4.1. UAE
          • 5.2.4.1.4.2. Saudi Arabia
          • 5.2.4.1.4.3. South Africa
          • 5.2.4.1.4.4. Rest of MEA
        • 5.2.4.1.5. South America
          • 5.2.4.1.5.1. Argentina
          • 5.2.4.1.5.2. Brazil
          • 5.2.4.1.5.3. Rest of South America

Chapter 6. North America Cardiovascular Devices Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. By Device Type
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country

Chapter 7. Europe Cardiovascular Devices Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. By Device Type
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country

Chapter 8. Asia Pacific Cardiovascular Devices Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. By Device Type
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country

Chapter 9. Middle East & Africa Cardiovascular Devices Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. By Device Type
    • 9.2.2. By Application
    • 9.2.3. By End User
    • 9.2.4. By Country

Chapter 10. South America Cardiovascular Devices Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. By Device Type
    • 10.2.2. By Application
    • 10.2.3. By End User
    • 10.2.4. By Country

Chapter 11. Company Profile (Company Overview, Company Timeline, Organization Structure, Key Product landscape, Financial Matrix, Key Customers/Sectors, Key Competitors, SWOT Analysis, Contact Address, and Business Strategy Outlook)

  • 11.1. Abbott
  • 11.2. BIOTRONIK SE & Co. KG
  • 11.3. Boston Scientific Corporation
  • 11.4. Canon Medical Systems
  • 11.5. B. Braun SE
  • 11.6. Cardinal Health
  • 11.7. Medtronic
  • 11.8. LivaNova PLC
  • 11.9. Siemens Healthcare GmbH
  • 11.10. Edwards Lifesciences Corporation
  • 11.11. GE Healthcare
  • 11.12. W. L. Gore & Associates, Inc.
  • 11.13. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제